2-[4-[[[5-(4-Ethylphenyl)-4-methyl-1,3-thiazole-2-carbonyl]amino]methyl]phenoxy]-2-methylpropanoic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[4-[[[5-(4-Ethylphenyl)-4-methyl-1,3-thiazole-2-carbonyl]amino]methyl]phenoxy]-2-methylpropanoic acid
• 化学式: C₂₄H₂₆N₂O₄S
• 分子量: 438.5
• InChiKey: VZXBQRCIGBRUII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Oxazol/thiazol-derivatives activators of the hppar-alpha receptor
  申请人：Gellibert Jeanne Francoise

  公开号：US20050070517A1

  公开（公告）日：2005-03-31

  A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof Wherein X 1 represents O or S; R 1 and R 2 are independently H or C 1-3 alkyl or R 1 and R 2 which are bonded to the same carbon atom may together with the carbon atom to which they are bonded form a 3-5 membered cycloalkyl ring; R 3 and R 4 independently represent H, halogen, —CH 3 and —OCH 3 ; R 5 represents H or C 1-6 alkyl X 2 represents NH, NCH 3 or O; One of Y and Z is N, and the other is O or S; R 6 represents phenyl or pyridyl (wherein the N is in position 2 or 3) and is optionally substituted by one or more halogen, CF 3 , C 1-6 straight or branched alkyl (optionally substituted by halogen), with the provision that when R 6 is pyridyl, the N is unsubstituted.

  式 (I) 的化合物及其药学上可接受的盐、溶剂和可水解酯 其中 X 1 代表 O 或 S； R 1 和 R 2 独立地为 H 或 C 1-3 烷基或 R 1 和 R 2 可与键合在同一碳原子上的碳原子一起形成一个 3-5 个成员的环烷基环； R 3 和 R 4 独立地代表 H、卤素、-CH 3 和 -OCH 3 ; R 5 代表 H 或 C 1-6 烷基 X 2 代表 NH、NCH 3 或 O；Y 和 Z 中的一个是 N，另一个是 O 或 S； R 6 代表苯基或吡啶基（其中 N 位于第 2 位或第 3 位），并可选择被一个或多个卤素、CF 3 , C 1-6 直链或支链烷基（可选择被卤素取代），但当 R 6 为吡啶基时，N 未被取代。
• OXAZOL/ THIAZOL-DERIVATIVES ACTIVATORS OF THE HPPAR-ALPHA RECEPTOR
  申请人：GLAXO GROUP LIMITED

  公开号：EP1399430A1

  公开（公告）日：2004-03-24
• USE OF PPAR AGONISTS TO TREAT RUMINANTS
  申请人：Pfizer Products Incorporated

  公开号：EP1765320A2

  公开（公告）日：2007-03-28
• Use of Ppar Agonists to Treat Ruminants
  申请人：Goetze Franz Leopold

  公开号：US20070232647A1

  公开（公告）日：2007-10-04

  The use of a PPAR agonist in the manufacture of a medicament to increase ruminant serum glucose concentrations, and preferably, the use for the palliative, prophylactic or curative treatment of ruminant disease associated with reduced serum glucose concentration. The ruminant disease associated with reduced serum glucose concentration includes fatty liver syndrome, dystocia, immune dysfunction, impaired immune function, toxification, primary ketosis, secondary ketosis, downer cow syndrome, indigestion, inappetence, retained placenta, displaced abomasum, mastitis, (endo-)-metritis, infertility, low fertility, lameness, subacute rumen acidosis and inadequate nutrient intake associated with stress e.g. heat, poor housing, overcrowding, shipping, dominance or illness, and to increase milk quality and yield.
• US7157479B2
  申请人：——

  公开号：US7157479B2

  公开（公告）日：2007-01-02